<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H25B1A1780A254DD294233D3BE491E899" key="H" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 HR 5854 IH: To allow the importation, distribution, and sale of investigational drugs and devices intended for use by terminally ill patients who execute an informed consent document.</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2014-12-11</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>2d Session</session>
		<legis-num>H. R. 5854</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20141211">December 11, 2014</action-date>
			<action-desc><sponsor name-id="G000556">Mr. Grayson</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title display="yes">To allow the importation, distribution, and sale of investigational drugs and devices intended for 
use by terminally ill patients who execute an informed consent document.</official-title>
	</form>
	<legis-body id="HD030454E17364C6AB2BF4C0D4308DB56" style="OLC">
		<section id="H08FD6F0EA8794569AADC3AD790FC68B5" section-type="section-one"><enum>1.</enum><header>Drugs and devices for use by terminally ill patients</header>
			<text display-inline="no-display-inline">The Federal Food, Drug, and Cosmetic Act is amended by inserting after section 561 (21 U.S.C.
			 360bbb) the following:</text><quoted-block display-inline="no-display-inline" id="idDE95FE7CFBEF4C7EB0C1902A91775AB3" style="OLC"><section id="id6A9FE5F1D87B412D806E869A3F12444D"><enum>561A.</enum><header>Drugs and devices for use by terminally ill patients</header><subsection id="id9A6F0553FC2B479A925EBE69B750BFB8"><enum>(a)</enum><header>In general</header><text>Nothing in this Act or section 351 of the Public Health Service Act prevents or restricts, and the
			 Food and Drug Administration shall not implement or enforce any provision
			 of law preventing or restricting, the importation, distribution, or sale
			 of an investigational drug or device intended for use by a terminally ill
			 patient in accordance with subsection (b).</text></subsection><subsection id="id979744153EF946C1BBE227938E60F83F"><enum>(b)</enum><header>Patient requirements</header><text>In order for an investigational drug or device to be intended for use in accordance with this
			 subsection, such drug or device must be intended for use by a patient who
			 has—</text><paragraph id="idF3CF6FAC3B9E455B96A21E61BF19A1CC"><enum>(1)</enum><text>been diagnosed with a terminal illness by a licensed physician;</text></paragraph><paragraph id="id2277C9C60E7249798EA52E17526FB330"><enum>(2)</enum><text>been informed by a licensed physician that no drug or device that is lawfully marketed in the
			 United States is likely to cure the illness; and</text></paragraph><paragraph id="id6A5FA53586F5434FAE2C626D0AE026C0"><enum>(3)</enum><text>executed a written informed consent document that states—</text><subparagraph id="id6C789B2C5BC34CAFA416DE770B9A8CFA"><enum>(A)</enum><text>the known and potential risks and benefits of such drug or device; and</text></subparagraph><subparagraph id="idB9510150094B430BB3FDF10C27FB8807"><enum>(B)</enum><text>any indications of the illness for which a drug or device is lawfully marketed, or for which
			 treatment is otherwise available, in the United States.</text></subparagraph></paragraph></subsection><subsection id="id5080A28F3BA24A6C8D5630A490A221E4"><enum>(c)</enum><header>Definition of investigational drug or device</header><text>In this section, the term <term>investigational drug or device</term> means a drug or device that—</text><paragraph id="idBC811F15C3FF4AE893D1966DCF6BA9B1"><enum>(1)</enum><text>has not yet been approved, licensed, or cleared for commercial distribution under section 505,
			 510(k), or 515 of this Act or section 351 of the Public Health Service Act
			 (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>), and cannot otherwise be lawfully marketed in the United
			 States; and</text></paragraph><paragraph id="id7E29FDAC133C4DE795C20398E2D67EB1"><enum>(2)</enum><text>is or has been the subject of one or more clinical trials.</text></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></section></legis-body>
</bill>


